A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China

Sponsor
Novartis Pharmaceuticals
Study ID
NCT04894890
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 100 Years
Healthy Volunteers
Not accepted

Interventions

  • secukinumab — DRUG
    There is no treatment allocation. Patients administered secukinumab by prescription that have started before inclusion of the patient into the study will be enrolled.

Study Details

This non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis (with and without PsA) initiating treatment of secukinumab.

Key Dates

Start date
Sep 26, 2021
Status verified
Mar 2024
Primary completion
Dec 15, 2023
Completion
Dec 15, 2023

Study Design

Enrollment
1,002 participants (actual)

Arms

  • Arm: secukinumab
    Patients administered secukinumab by prescription

Primary Outcome Measure

Percentage of patients achieving a 90% reduction in the Psoriasis Area and Severity Index (PASI) score [ Time Frame: week 24 ]

Related Studies